Dallas, Texas 01/15/2014 (FINANCIALSTRENDS) – Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is a $68.20 million Biotechnology company with core expertise in delivery of oxygen after a trauma, to specific target tissues. The volume’s for the company are 2,562, 287 and trades between the range of 52week high of $15.90 and 52-week low of $1.10. The EPS is -6.29. Ladenburg Thalmann says the oxygen-delivery drug the company is currently tests as part of its clinical trials is expected to deliver high sales.
Oxygen Biotherapeutics, Inc. reported in the mid-week of June that it has finished with the trails, which were in the pre-clinical stage to evaluate lead drug candidate – Oxycte. The drug has since been tested for the potential or probable class of effects it would cause on the immune system of the body or patient. The drug which Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) look to offer is classified as a perflurocarbon, which operates as a carrier of oxygen. It will be used for multiple stages. The main line of action is to look at the ability of the drug to improve or deliver oxygen, to the brain. When a person is injured and there is high trauma, the main focus is to ensure the oxygen is delivered to the brain. Lack of oxygen could cause several problems and other medical issues. If there is acute damage to the brain then the complications are often life-long and nearly irreversible.
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) has continued to work on the delivery systems of drugs to ensure the brain receives required quantity of oxygen in post-trauma conditions. Typically coma and other advanced atrophy conditions are immediate and the efficacy of drugs such as Oxcyte could well make the difference for a patient to ensure that organs remain unaffected. Besides, Oxycyte is expected to further help, as there its applications as a multiple potential is enormous.